Germline testing should be done in all newly diagnosed patients with pancreatic cancer, recommends O’Reilly. There is about a 10% chance that a pathogenic germline mutation will be found that is significant to the patient or family, adds O’Reilly. This can lead to cascade testing family members who may be at risk for pancreatic cancer or other malignancies as well as identify a familial genetic syndrome. Watch here . . .